NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017

Mary B. Daly(Fox Chase Cancer Center), Robert Pilarski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michael P. Berry(St. Jude Children's Research Hospital), Saundra S. Buys(University of Utah), Meagan Farmer(University of Alabama at Birmingham), Susan Friedman(Facing Our Risk of Cancer Empowered), Judy E. Garber(Dana-Farber Brigham Cancer Center), Noah D. Kauff(Cancer Institute (WIA)), Seema Khan(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Catherine Klein(University of Colorado Denver), Wendy Kohlmann(University of Utah), Allison W. Kurian(Stanford Cancer Institute), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Lisa Madlensky(Moores Cancer Center), Sofía D. Merajver(University of Michigan–Ann Arbor), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Tuya Pal(Pfizer (United Kingdom)), Gwen Reiser(Fred and Pamela Buffett Cancer Center), Kristen M. Shannon(Massachusetts General Hospital), Elizabeth M. Swisher(University of Washington Medical Center), Shaveta Vinayak(University Hospitals Seidman Cancer Center), Nicoleta Voian(Roswell Park Comprehensive Cancer Center), Jeffrey N. Weitzel(City of Hope), Myra Wick(WinnMed), Georgia L. Wiesner(Vanderbilt-Ingram Cancer Center), Mary A. Dwyer(National Comprehensive Cancer Network), Susan Darlow(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
December 31, 2016
Cited by 659Open Access
Full Text

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer.


Related Papers

No related papers found

Powered by citation graph analysis